YIA

Four Early-Career Cancer Researchers Earn Prestigious Annual Award from NCCN Foundation

Retrieved on: 
Thursday, April 13, 2023

PLYMOUTH MEETING, Pa., April 13, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® today announced four winners for the 2023 NCCN Foundation Young Investigator Awards. These annual awards honor up-and-coming leaders in oncology research working to investigate and advance cancer care. The honorees will each receive up to $150,000 in funding for projects that will run over two years. The selection process is overseen by the NCCN Oncology Research Program (ORP) which will also provide oversight.

Key Points: 
  • National Comprehensive Cancer Network's Oncology Research Program to oversee projects focused on kidney cancer, palliative care, detection of early-stage cancer, and racial differences in breast cancer.
  • PLYMOUTH MEETING, Pa., April 13, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® today announced four winners for the 2023 NCCN Foundation Young Investigator Awards .
  • The 2023 NCCN Foundation YIA recipients are:
    Julia Agne, MD, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
    The four researchers, who are all from NCCN Member Institutions, will present their results at a future NCCN Annual Conference.
  • The NCCN Foundation has awarded more than $10.3 million since 2011 through the YIA program, to a total of 70 researchers.

Dr. Rushil V. Patel named 2022 recipient of The Conquer Cancer – Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care

Retrieved on: 
Thursday, September 8, 2022

Lugano, Switzerland, September 8, 2022 - Helsinn Group (Helsinn), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, in conjunction with Conquer Cancer, the ASCO Foundation, announces today Dr. Rushil V. Patel as the 2022 recipient of the Conquer Cancer - Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care.

Key Points: 
  • Lugano, Switzerland, September 8, 2022 - Helsinn Group (Helsinn), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, in conjunction with Conquer Cancer, the ASCO Foundation, announces today Dr. Rushil V. Patel as the 2022 recipient of the Conquer Cancer - Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care.
  • Helsinn established the Anna Braglia Endowed Young Investigator Award (YIA) through an endowment to Conquer Cancer.
  • The Conquer Cancer - Anna Braglia Endowed YIA in Cancer Supportive Care was established in 2016 to honor the life of Anna Braglia, the wife of Helsinn Group Founder and Chairman, Gabriele Braglia, and mother of Helsinn Group Executive Chairman, Riccardo Braglia, following her passing in 2015.
  • Dr. Rushil V. Patel, commented: Receiving the Young Investigator Award for a subject that is so close to my heart is a true honor.

Women Leaders in Oncology® Presents Dr Susan Scott the 2022 WLO "Women Who Conquer Cancer" Young Investigator Award

Retrieved on: 
Thursday, June 16, 2022

CHICAGO, June 16, 2022 /PRNewswire/ -- Last night at its 9th annual reception, the Women Leaders in Oncology® (WLO) presented the 2022 WLO "Women Who Conquer Cancer" Young Investigator Award (YIA) to Susan Scott, MD, a thoracic medical oncologist and assistant professor of oncology at the Johns Hopkins University School of Medicine. In addition, the hundreds of women who attended the virtual gathering made significant financial contributions to help fund future YIAs for women conducting promising research within the field of oncology.

Key Points: 
  • In addition, the hundreds of women who attended the virtual gathering made significant financial contributions to help fund future YIAs for women conducting promising research within the field of oncology.
  • The keynote speaker of the 2022 WLO annual reception was Sonali M. Smith, MD, section chief of hematology/oncology at the University of Chicago Medicine.
  • This year's recipient of the WLO Women Who Conquer Cancer YIA is Susan Scott, MD, a thoracic medical oncologist and assistant professor of oncology at the Johns Hopkins University School of Medicine.
  • Dr Scott received her undergraduate education at the University of Oxford and medical doctorate from Yale University.

Vaniam Group Announces Chijioke Nze, MD, MPH, as the 2022 Recipient of Conquer Cancer-Vaniam Group LLC Young Investigator Award

Retrieved on: 
Wednesday, May 25, 2022

CHICAGO, May 25, 2022 /PRNewswire/ -- Vaniam Group announced today that the second annual Conquer Cancer-Vaniam Group LLC Young Investigator Award (YIA) was bestowed upon Chijioke Nze, MD, MPH, from the University of Texas MD Anderson Cancer Center. Funded by Vaniam Group, this annual award provides research grants to Black, African, or African American researchers who specialize in oncology.

Key Points: 
  • Funded by Vaniam Group, this annual award provides research grants to Black, African, or African American researchers who specialize in oncology.
  • I am grateful to Vaniam Group and Conquer Cancer for recognizing the importance of this research, and for providing the grant that makes it possible."
  • Founded in 2007 as a virtual-by-design organization, Vaniam Group harnesses the talents and expertise of team members around the world.
  • Their mission is to conquer cancer worldwide by funding breakthrough research and sharing cutting-edge knowledge.

NCCN Foundation Announces Awards for Rising Cancer Research Leaders

Retrieved on: 
Monday, April 25, 2022

PLYMOUTH MEETING, Pa., April 25, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® today announced seven recipients for the 2022 NCCN Foundation  Young Investigator Awards (YIA) Program. The honorees will each receive up to $150,000 in funding, over two years, to advance research on important issues in oncology. These early-career investigators from NCCN Member Institutions represent tomorrow's leaders for advancing cancer care. The NCCN Oncology Research Program (ORP) managed the selection process and will provide guidance and oversight for the projects over the grant duration.

Key Points: 
  • "NCCN Foundation Young Investigator Award recipients make important contributions to treatment innovation and advancement for people with cancer.
  • To learn more about the 2022 NCCN Foundation Young Investigator Awards or to make a donation to the NCCN Foundation, visit NCCN.org/Foundation .
  • The National Comprehensive Cancer Network ( NCCN ) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education.
  • The NCCN Foundation is also committed to advancing cancer treatment by funding the nation's promising young investigators at the forefront of cancer research.

Y-mAbs Hosting Virtual Research and Development Day

Retrieved on: 
Monday, December 6, 2021

NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it will host a virtual research and development day on Wednesday, December 15, 2021 at 12pm Eastern Time.

Key Points: 
  • NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it will host a virtual research and development day on Wednesday, December 15, 2021 at 12pm Eastern Time.
  • The Y-mAbs research and development day will feature presentations from oncology key opinion leaders (KOLs) Javier E. Oesterheld, M.D.
  • Hes also the principal investigator for Carolinas Kids Cancer Research Coalition, in conjunction with the developmental therapeutics program at Levine Childrens Hospital.
  • Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.

Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma

Retrieved on: 
Friday, September 10, 2021

This webinar will feature presentations from KOLs Jaume Mora, M.D., Ph.D., SJD Barcelona Children's Hospital, and Shakeel Modak, M.D., MRCP, Memorial Sloan Kettering.

Key Points: 
  • This webinar will feature presentations from KOLs Jaume Mora, M.D., Ph.D., SJD Barcelona Children's Hospital, and Shakeel Modak, M.D., MRCP, Memorial Sloan Kettering.
  • Shakeel Modak, M.D., MRCP is a pediatric hematology-oncology doctor at Memorial Sloan Kettering Cancer Center, Department of Pediatrics in New York.
  • degrees from TN Medical College, Bombay, as well as his MRCP degree from Royal College of Physicians, London.
  • Dr. Modak specializes in the treatment of children and young adults with neuroblastoma and other solid tumors, such as DSRCT.